Medicover AB (MCVEY) Fair Value & Analysis
Healthcare · US · Market cap $2.5B
Medicover AB
MCVEY · US
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from $26.02 to $11.06 (−57.5%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $16.32 – $16.55 · fair‑value band $7.49 – $16.08 · the $16.55 price screens above the $11.06 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medicover AB (MCVEY) currently trades at $16.55, while our model-based Fair Value estimate is $11.06 — implying the stock looks roughly 33.2% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medicover AB generated revenue of $2.4B at a net margin of 3.3%. Revenue grew 8.0% year over year. It earns a return on equity of 13.9%. Net debt stands at $1.4B. Fundamentals as of Jul 5, 2026
Our scenario range runs from $7.49 (bear case) to $16.08 (bull case); at $16.55, the current price sits above that range. The share trades about 22% below its 52-week high and 1% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside — at -33%, MCVEY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medicover AB reported revenue of $2.4B in FY2025 versus $1.4B in FY2021, a compound +14.6%/yr. Reported net income was $77.5M in FY2025, compounding −6.6%/yr from FY2021.
Is MCVEY fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Fresenius Medical Care AG FMS | $23.59 | $34.71 | +47% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,489 | ₹2,128 | -75% |
| DaVita Inc DVAI34 | R$1,030 | R$1,096 | +7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicover AB (MCVEY) undervalued?
What is the fair value of MCVEY?
What is the quality score of MCVEY?
What is the revenue of Medicover AB (MCVEY)?
What is the net profit margin of MCVEY?
Does Medicover AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.